Logo
x

Search

Subscribe Now

AbbVIe

AbbVie to Bolster its Immunology Pipeline Through the Acquisition of Nimble Therapeutics

AbbVie to Bolster its Immunology Pipeline Through the Acquisition of Nimble Therapeutics

  • December 16, 2024
AbbVie Reports Results from the P-III (TEMPO-2) Study of Tavapadon for Parkinson's Disease

AbbVie Reports Results from the P-III (TEMPO-2) Study of Tavapadon for Parkinson's Disease

  • December 10, 2024
AbbVie and Genmab Highlight P-I/II (EPCORE NHL-2) Study Data of Epcoritamab to Treat R/R Follicular Lymphoma (FL) at ASH 2024

AbbVie and Genmab Highlight P-I/II (EPCORE NHL-2) Study Data of Epcoritamab to Treat R/R Follicular Lymphoma (FL) at ASH 2024

  • December 9, 2024
AbbVie’s Elahere (Mirvetuximab Soravtansine) Receives the EC’s Approval to Treat Platinum-Resistant Ovarian Cancer

AbbVie’s Elahere (Mirvetuximab Soravtansine) Receives the EC’s Approval to Treat Platinum-Resistant Ovarian Cancer

  • November 18, 2024
AbbVie Reports the P-II (EMPOWER) Studies Data of Emraclidine for Treating Schizophrenia

AbbVie Reports the P-II (EMPOWER) Studies Data of Emraclidine for Treating Schizophrenia

  • November 12, 2024
AbbVie Join Forces with EvolveImmune Therapeutics for Developing Next-Generation Biotherapeutics in Oncology

AbbVie Join Forces with EvolveImmune Therapeutics for Developing Next-Generation Biotherapeutics in Oncology

  • November 4, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.